You can be fraid of whatever you want. It is absolutely true. SNY is in control of Marketing. They take 65% and in return they have full responsibility for sales and marketing. For all intents and purposes, they own Afrezza, and MNKD receives what is effectively royalties.
If you said, maybe SNY will buy the plant from MNKD some day, I'd say that is a possibility. But the rest is written down and in stone. That and Hakan being CEO makes it clear that they aren't hiding anything. You don't need to hatch conspiracy theories to be excited about this stock.
The afrezza question has been answered multiple times. SNY has control over the launch. It's that simple.
He can buy. He just needs to disclose. He's shared all information including a LymPro spinoff. It is not appropriate for him to say he'd be buying all day long though.
Last time I answer this because it is really inane. AMBS has never earned revenues and yet people make money trading it all the time. There are investors who favor bio plays that haven't made a dime. They but before inflection points and could lose it all or coild make a fortune. These stocks become more valuable as the drugs become less risky. Each new phase a drug enters makes it less risky until it is FDA approved. Their model, in theory, is to buy undervalued drugs and derisk through completing more research and advancing trials. If successful it will be wildly profitable for investors. If unsuccessful AMBS will most likely go out of business.
This is a spec play consisting of numerous spec plays. If you don't trust it will work you shouldn't be invested. No harm no foul. If you think it could, you should, as long as you are aware of the risks.
This is VERY high risk VERY high reward scenario. You can debate it on its risks, but stop trying to tell everyone things that don't make revenues can't be profited from handsomely. You are taking to biotech investors, most of whom have made money on things that don't generate revenue. It isn't even a scare tactic, it just makes you look stupid.
You can also look at: "Amarantus Exercises Option To License Intellectual Property From University Of Miami Bascom Palmer Eye Institute For Use Of MANF In Retinal Disorders"
Happened in AUGUST, which is a few months after you said you came in. For an investor that sounds very knowledgeable, you sure don't have much knowledge.
Buy assets which are for whatever reason out of favor. Sell them at a higher value. Not a proven business model but it is the AMBS business model. Did you know that? I think you did but I might be putting too much stock in you.
My point is that your argument that if something makes no revenues it doesn't have a value lacks in reason and can be easily disproved by countless examples. If you stand by that belief, you, too, lack in reason. This isn't even a matter of credibility: It is a matter of having brain cells which fire correctly. Lacking that, your words, as you say, "lack revenue".
They've purchased a lot of things without revenue. This has a value and no revenue. How in the world is your point even remotely sensible I the real world?
Anyone who has ever gotten rich off of penny plays is likely to go broke doing the same thing. Trading penny stocks is very dangerous. Holding a penny stock long term is a pretty risky thing to do, even when everything is perfect. This company seems to have the right stuff. 2014 was disappointing for anyone who held through the Money Runners pump.
I'll be honest... I made my first sale at the end of the year to get rid of some of my red shares. On measure, I was always up, but I figured I'd take the opportunity to do some tax loss selling and put more of my funds in other investments. Still have a good amount of shares (for me), and my outlook has not changed.
But it is always important to review your portfolio and investment goals. If you're getting frustrated or impatient, it may mean you're putting too many eggs in this basket.
Two former stocks which were heavily shorted only to go on monster runs in short periods of time. MNKD will do this too in 2015. Long-term call options are dirt cheap thanks to shorts. Thank them profusely and enjoy a 3+ bagger with options. I'm not one who thinks this will run to $50 in the next few years, but I definitely see it reaching $15-$20 with favorable market conditions and some good Afrezza sales coupled with high profile Technosphere news by the end of 2016. Buy some 2015 or 2016 call options between $7-$10 if you have the risk tolerance for it and you are a long. Just my opinion.
So there is more than zero, meaning you were wrong. One patent is all you need if it's a good one. And it may be a small piece of technology, but lots of money was spent on developing it. If the size of something was directly proportional to its value, we'd all be working on 12TB solid state hard drive computers with I6 processors right now.
Barring disastrous news, shorts have pretty much sucked all the weak hands out of this stock. It is a battleground stock, so it can break big one way or the other, but shorts don't really have any more fuel for their fire, so all that's left to is for longs to sell. As long as the longs are not selling, the price will not be breaking below $5.
Manipulation only gets you so far.
Stats are up however it's still a little misleading because we didn't see results from the full 75 data set. I think licensing gtown Dx was brilliant because I think it is clear LymPro cannot stand on its own. With Georgetown tests no longer posing an imminent threat though LymPro will have a good basis with the MS test providing most of the near term growth.
Yes good hint, but they've dropped hints before. I think they signaled they'd uplist by the end of 2014 with bonus payouts. IMO, this is more of a signal about a Dx spin-off. I think Gerald won't uplist earlier than 2H, but given past events I doubt he will uplist unless the spin-off produces big interest and our business model is validated. If and when that happens we should see moves to uplist, but Gerald is very sensitive to the RS scaredy cats. Too sensitive if you ask me.
If Gerald learned his lesson he'll have taken the time to factor in statistical probability as well to include that. It would easily bump accuracy over 90%. That's how they presented the recent merger anyway.
It's palatable, is it? I think you meant palpable. NBD, typos happen all the time, but that was a funny misuse of words.
It would have been far more cost effective to buy a tenth as many for ten times as much expiring in Jan 2016 or 2017 at a higher strike price. That is an easy 4-5 bagger and you get long term gains with much less risk of timing.